Association of Plasma PTX3 Concentration and Outcomes of STEMI

STEMI Clinical Trial

Official title:

Association of Plasma Pentraxin 3 Concentration With Angiographic and Clinical Outcomes in STEMI Treated by Primary Angioplasty

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03894176
• Other study ID #: IndonesianCRC
• Status: Completed
• Start date: January 1, 2018
• Est. completion date: September 2, 2018

Study information

• Verified date: March 2019
• Source: Indonesian Cardiovascular Research Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

335 of patients with STEMI treated by primary PCI were assayed for PTX3 measurement by ELISA method. The angiographic and clinical outcomes were evaluated according to the PTX3 concentration.

Description:

335 of patients with STEMI treated by primary PCI were assayed for PTX3 measurement by ELISA method using human PTX3 kit. Blood was drawn at the emergency department before primary PCI. The angiographic and clinical outcomes were evaluated and analyzed according to the PTX3 concentration. The angiographic outcome were thrombus grade on initial angiogram and final TIMI flow. The clinical outcome were ECG resolution after primary PCI and all-cause death at 30 days. The plasma PTX3 concentration was then compared based on the outcomes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 335
• Est. completion date: September 2, 2018
• Est. primary completion date: August 2, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with acute STEMI with symptom onset <12 h undergoing primary PCI

Exclusion Criteria:

• Acute STEMI patients who received fibrinolytic therapy

Related Conditions & MeSH terms

• Coronary; Ischemic
• ST Elevation Myocardial Infarction
• STEMI

Intervention

Other:
• Plasma PTX3 concentration
Long pentraxin 3, thrombus burden, final TIMI flow, ST segment resolution, STEMI, primary PCI

Locations

Country	Name	City	State
Indonesia	Indonesian Cardiovascular Research Center	Jakarta	DKI Jakarta

Sponsors (1)

Lead Sponsor	Collaborator
Indonesian Cardiovascular Research Center

Country where clinical trial is conducted

Indonesia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of thrombus grade 4&5 and final TIMI flow <3	PTX3 concentration was compared based on the outcome	Intraprocedure